Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a lysosomal storage disease that is characterized by systemic clinical manifestations and significant functional impairment. Diagnosis and management are often challenging because of the considerable variability in symptom presentation and rate of progression. The optimal standard of care should be based on evidence from randomized, controlled trials, meta-analyses, systematic reviews, and expert opinion. In support of this goal, comprehensive management guidelines have been drafted by an international group of experts in the management of patients with mucopolysaccharidosis VI. The guidelines provide a detailed outline of disease manifestations by body system, recommendations for regular assessments, and an overview of current treatment options.
Skip Nav Destination
Article navigation
August 2007
Special Articles|
August 01 2007
Management Guidelines for Mucopolysaccharidosis VI
Roberto Giugliani, MD, PhD;
Roberto Giugliani, MD, PhD
aMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Search for other works by this author on:
Paul Harmatz, MD;
Paul Harmatz, MD
bChildren's Hospital and Research Center Oakland, Oakland, California
Search for other works by this author on:
James E. Wraith, MD
James E. Wraith, MD
cWillink Biochemical Genetics Unit, Royal Manchester Children's Hospital, Manchester, United Kingdom
Search for other works by this author on:
Address correspondence to Paul Harmatz, MD, Children's Hospital and Research Center Oakland, 744 52nd St, Oakland, CA 94609. E-mail: pharmatz@mail.cho.org
Pediatrics (2007) 120 (2): 405–418.
Article history
Accepted:
March 28 2007
Citation
Roberto Giugliani, Paul Harmatz, James E. Wraith; Management Guidelines for Mucopolysaccharidosis VI. Pediatrics August 2007; 120 (2): 405–418. 10.1542/peds.2006-2184
Download citation file:
0 Comments
Comments Icon
Comments (0)
Sign in
Don't already have an account? Register
Pay-Per-View Access
$25.00